Toronto, Ontario – May 27, 2026 - TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is providing the following update with respect to its previously announced proposed acquisition (the " Transaction ") of approximately 54.01% of the issued and outstanding ordinary shares (the “ Purchased Shares ”) of CliniQuantum Ltd. (" CliniQuantum "), as initially announced by news release dated March 10, 2026. The Company is providing this news release to supplement the disclosure contained in its March 10, 2026 news release, including in respect of (i) the license agreement between CliniQuantum and Quantum X Labs Ltd., (ii) the basis for the consideration payable under the Transaction and the fairness opinion received by the Company's board of directors, (iii) certain amendments to the share purchase agreement dated March 9, 2026 (the “ SPA ”) between the Company, CliniQuantum and the holders of the Purchased Shares (the “ Selling Shareholders ”), including the establishment of a floor price for future share issuances, an extension of the outside date, and the execution of lock-up arrangements by the Selling Shareholders as a condition of closing.
